Stock detail

RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine Sanayi Ticaret A.Ş.

RTALBSTOCKS | TR | IST | Healthcare | Biotechnology

Profile snapshotTRY 2Market cap TRY 990M

No local candle data found.

Recent detected patterns / setups

Latest 10 Market Radar results for this symbol and selected direction.

PatternTFScan runQuality

BullishOliver Kell Momentum Setup4H07 Nov 26, 16:1673

BullishMA 8/21 Crossover4H07 Nov 26, 16:1690

BearishICT Inverse FVG Setup4H07 Nov 26, 16:16100

BullishShark4H07 Nov 26, 16:0967

BullishCrab4H07 Nov 26, 16:0971

BearishSupport/Resistance Flip Setup15M07 Nov 26, 09:1473

BullishMA 8/21 Crossover15M07 Nov 26, 09:1477

BullishICT Inverse FVG Setup15M07 Nov 26, 09:1480

BearishICT Optimal Trade Entry (OTE) Setup15M07 Nov 26, 09:1483

BullishOliver Kell Momentum Setup15M07 Nov 26, 09:1483

About RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine Sanayi Ticaret A.Ş.

RTA Laboratuvarları Biyolojik Ürünler İlaç ve Makine Sanayi Ticaret A.Ş. (RTALB) is listed on IST. Sector: Healthcare. Industry: Biotechnology.

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers real-time PCR kits, nucleic acid extraction kits, microbiology media, microbiology stains, and rapid tests; standards and reference materials, and membrane filters; chemicals and reactives, membrane filters, microbiology gas generators, and other consumables; and instruments and consumables. RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. was incorporated in 1996 and is based in Kocaeli, Turkey.

Annual

Annual fundamentals

2025 vs previous annual period

Total revenueTRY 239.6M+15.4%

Net incomeTRY 881.2M+1188.8%

Net profit margin367.8%+334.9 pp

EPS1.76+157.8%

Total debtTRY 119.1M-59.3%

Cash and cash equivalentsTRY 4.7M-44.8%

Net debtTRY 114.4M-59.8%

Metric20212022202320242025

Total revenue----TRY 191.3M--TRY 138.5M-27.6%TRY 207.6M+49.9%TRY 239.6M+15.4%

Net income----TRY 155.9M--TRY -103.2M-166.2%TRY 68.4M+166.3%TRY 881.2M+1188.8%

Net profit margin----81.5%---74.5%-191.4%32.9%+144.2%367.8%+1016.8%

EPS----0.31---0.21-166.2%0.68+431.3%1.76+157.8%

Free cash flow----TRY -772,663--TRY 23.9M+3197.5%TRY -236.8M-1089.4%TRY 121M+151.1%

Total debt----TRY 115.1M--TRY 67M-41.8%TRY 292.9M+337.1%TRY 119.1M-59.3%

Cash and cash equivalents----TRY 51.7M--TRY 47.2M-8.7%TRY 8.5M-81.9%TRY 4.7M-44.8%

Net debt----TRY 63.4M--TRY 19.8M-68.7%TRY 284.4M+1332.6%TRY 114.4M-59.8%

Quarterly

Quarterly fundamentals

Q2 2026 vs same quarter previous year

Total revenueTRY 83.8M+1.5%

Net incomeTRY -247.4M+17.0%

Net profit margin-295.2%+66.1 pp

EPS-0.5+17.0%

Total debtTRY 21.9M-40.2%

Cash and cash equivalentsTRY 74.6M+827.3%

Net debtTRY -52.7M-284.3%

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Total revenueTRY 68.4M--TRY 65.8M------TRY 74.4M--TRY 82.6M+20.8%TRY 83.8M+27.3%

Net incomeTRY 281.3M--TRY 121.2M------TRY 483M--TRY -298.3M-206.0%TRY -247.4M-304.1%

Net profit margin411.6%--184.1%------649.4%---361.3%-187.8%-295.2%-260.4%

EPS0.56--0.24-----------0.6-206.0%-0.5-304.5%

Free cash flow----TRY 25.6M--TRY -34.6M--TRY -19.2M--TRY 120.4M--TRY -94.5M-469.2%

Total debtTRY 162.6M--TRY 66.8M------TRY 119.1M--TRY 36.6M-77.5%TRY 21.9M-67.2%

Cash and cash equivalentsTRY 6.1M--TRY 4.9M------TRY 4.7M--TRY 8M+31.4%TRY 74.6M+1422.4%

Net debtTRY 156.5M--TRY 61.9M------TRY 114.4M--TRY 28.6M-81.7%TRY -52.7M-185.1%

Ownership

Institutional ownership summary

2026 Q3, quarter ended 2026-08-21

PeriodOwnershipInstitutions13F sharesTotal investedPositionsPut/call

2026 Q3